Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
1Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
© 2018 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Values are presented as mean ± SD, number (%), or mean (IQR).
IUGR, intrauterine growth retardation; RDS, respiratory distress syndrome; PDA, patent ductus arteriosus; BPD, bronchopulmonary dysplasia; IVH, intraventricular hemorrhage; PVL, periventricular leukomalacia; NEC, necrotizing enterocolitis; ROP, retinopathy of prematurity; VEGF, vascular endothelial growth factor; LOS, late-onset sepsis; SD, standard deviation; IQR, interquartile range.
Variable | Non-CPI (n = 312) | CPI (n = 90) | p-value |
---|---|---|---|
Gestational age (wk) | 29.1 ± 2.9 | 28.4 ± 3.2 | .007* |
Birth weight (g) | 1,064.7 ± 286.9 | 1,012.5 ± 309.1 | .589 |
Sex | .506 | ||
Male | 154 (49.3) | 48 (53.3) | |
Female | 158 (50.6) | 42 (46.7) | |
Pre-eclampsia | 78 (25.0) | 9 (10.0) | .031* |
Antenatal steroid use | 284 (91.0) | 79 (87.8) | .398 |
IUGR | 107 (34.3) | 26 (28.9) | .338 |
RDS | 177 (56.7) | 61 (67.8) | .068 |
Significant PDA | 127 (40.7) | 40 (44.4) | .531 |
Moderate to severe BPD | 79 (25.3) | 26 (28.9) | .497 |
Postnatal steroid therapy | 72 (23.1) | 24 (26.7) | .496 |
Duration of oxygen supply (day) | 41.4 ± 38.2 | 41.0 ± 38.1 | .163 |
Severe neurologic injury (IVH ≥ grade 3 or PVL) | 34 (10.9) | 9 (10) | .051 |
NEC (≥ stage 2) | 15 (4.8) | 4 (4.4) | .882 |
LOS | 65 (20.8) | 23 (25.6) | .164 |
ROP (any stage) | 71 (22.8) | 26 (28.9) | .021* |
Type 1 ROP | 27 (8.6) | 19 (21.1) | .003* |
Hospital days (day) | 66.5 ± 36.0 | 72.6 ± 36.1 | .154 |
Values are presented as mean ± SD or number (%).
CPI, chronic placental inflammation; IUGR, intrauterine growth retardation; RDS, respiratory distress syndrome; PDA, patent ductus arteriosus; BPD, bronchopulmonary dysplasia; IVH, intraventricular hemorrhage; PVL, periventricular leukomalacia; NEC, necrotizing enterocolitis; LOS, late-onset sepsis; ROP, retinopathy of prematurity; SD, standard deviation.
*p < .05.
Variable |
Any stage ROP |
Type 1 ROP |
||||||
---|---|---|---|---|---|---|---|---|
No ROP (n = 305) | ROP (n = 97) | OR (95% CI) | p-value | No type 1 ROP (n = 356) | Type 1 ROP (n = 46) | OR (95% CI) | p-value | |
Gestational age (wk) | 30.0 ± 2.5 | 25.7 ± 1.7 | 0.872 (0.847–0.897) | < .001* | 30.4 ± 2.8 | 25.1 ± 1.5 | 0.882 (0.853–0.911) | < .001* |
Birth weight (g) | 1,152.5 ± 239.5 | 740.6 ± 212.9 | 0.993 (0.992–0.995) | < .001* | 1100 ± 267.7 | 680.8 ± 198.7 | 0.993 (0.991–0.995) | < .001* |
Male | 157 (51.5) | 49 (50.5) | 1.000 (0.329–1.126) | .339 | 179 (50.3) | 23 (50.0) | 1.000 (0.504–1.305) | .219 |
Pre-eclampsia | 62 (20.3) | 7 (7.2) | 0.919 (0.383–2.205) | .851 | 66 (18.5) | 3 (6.5) | 0.295 (0.089–0.981) | .046* |
Antenatal steroid | 271 (88.9) | 92 (94.8) | 1.547 (0.484–4.942) | .461 | 321 (90.2) | 42 (91.3) | 1.145 (0.388–3.382) | .807 |
IUGR | 114 (37.3) | 19 (19.6) | 0.369 (0.323–1.265) | .199 | 125 (35.1) | 8 (17.4) | 0.389 (0.176–0.860) | .020* |
Moderate to severe BPD | 40 (13.1) | 65 (67.0) | 0.503 (0.361–0.508) | < .001* | 67 (18.8) | 38 (82.6) | 0.467 (0.281–0.410) | < .001* |
Postnatal steroid therapy | 34 (11.1) | 62 (63.9) | 0.512 (0.380–0.531) | < .001* | 60 (16.8) | 36 (78.3) | 0.399 (0.382–0.606) | < .001* |
Duration of oxygen treatment (day) | 27.9 ± 26.1 | 81.2 ± 42.7 | 1.054 (1.042–1.066) | < .001* | 33.5 ± 31.3 | 98.6 ± 38.4 | 1.044 (1.031–1.057) | < .001* |
Placental pathology | ||||||||
CPI | 64 (21.0) | 26 (26.8) | 2.050 (1.170–3.592) | .038* | 71 (19.9) | 19 (46.3) | 2.825 (1.487–5.367) | .002* |
CCA | 33 (10.8) | 10 (10.3) | 0.159 (0.691–3.152) | .159 | 36 (10.1) | 7 (15.2) | 1.590 (0.663–3.816) | .299 |
Chronic deciduitis | 29 (9.5) | 12 (12.4) | 0.244 (0.874–3.872) | .244 | 33 (9.3) | 8 (17.4) | 2.061 (0.887–4.784) | .093 |
VUE | 13 (4.3) | 2 (2.1) | 0.139 (0.042–2.501) | .139 | 15 (4.2) | 0 | 0.237 (0.013–4.413) | .335 |
ACA | 53 (17.4) | 32 (33.0) | 2.079 (1.177–3.671) | .012* | 70 (19.7) | 15 (32.6) | 1.977 (1.012–3.862) | .046* |
MVU | 118 (38.7) | 31 (32.0) | 0.744 (0.452–1.344) | .744 | 134 (37.6) | 15 (32.6) | 0.802 (0.417–1.540) | .507 |
FVTOD | 29 (9.5) | 11 (11.3) | 0.806 (0.325–2.000) | .642 | 36 (10.1) | 4 (8.7) | 0.847 (0.287–2.498) | .763 |
Values are presented as mean ± SD or number (%).
ROP, retinopathy of prematurity; OR, odds ratio; CI, confidence interval; IUGR, intrauterine growth retardation; BPD, bronchopulmonary dysplasia; CPI, chronic placental inflammation; CCA, chronic chorioamnionitis; VUE, villitis of unknown etiology; ACA, amniotic fluid infection/inflammation; MVU, maternal vascular underperfusion; FVTOD, fetal vascular thrombo-occlusive disease; SD, standard deviation.
*p < .05.
Placental pathology |
No ROP |
Any stage ROP |
Type 1 ROP |
|||
---|---|---|---|---|---|---|
Adjusted OR (95% CI) | p-valuea | Adjusted OR (95% CI) | p-valuea | Adjusted OR (95% CI) | p-valuea | |
CPI | 1.008 (0.492–2.068) | .982 | 1.647 (0.702–3.992) | .246 | 2.739 (1.112–6.749) | .029* |
ACA | 0.811 (0.429–1.940) | .811 | 1.267 (0.531–3.023) | .594 | 0.833 (0.319–2.173) | .708 |
MVU | 0.630 (0.315–1.261) | .630 | 2.036 (0.865–4.792) | .103 | 0.570 (0.211–1.539) | .267 |
FVTOD | 0.815 (0.298–2.226) | .690 | 1.080 (0.360–3.240) | .126 | 0.424 (0.141–1.272) | .126 |
Chronic placental inflammation was statistically associated with type 1 ROP by multiple logistic regression analysis.
ROP, retinopathy of prematurity; OR, odds ratio; CI, confidence interval; CPI, chronic placental inflammation; ACA, amniotic fluid infection/inflammation; MVU, maternal vascular underperfusion; FVTOD, fetal vascular thrombo-occlusive disease.
*p < .05.
aAdjusted for gestational age, birth weight, sex, duration of oxygen treatment, pre-eclampsia, IUGE and the overlapping placental pathology.
Variable | Value (n = 402) |
---|---|
Neonatal characteristics | |
Gestational age (wk) | 28.5 ± 2.8 |
Birth weight (g) | 1,027.2 ± 304.4 |
Male | 206 (51.2) |
Multiple births | 94 (23.4) |
Maternal age (yr) | 33.6 ± 17.1 |
Pre-eclampsia | 69 (16.9) |
Cesarean section | 305 (75.1) |
Antenatal steroid use | 363 (90.3) |
Apgar score at 1 min | 5.0 (3–7) |
Apgar score at 5 min | 7.0 (1–9) |
IUGR | 133 (33.1) |
Neonatal morbidity | |
RDS | 238 (59.2) |
Significant PDA | 167 (41.5) |
Moderate to severe BPD | 105 (26.1) |
Postnatal steroid therapy | 96 (23.9) |
Duration of oxygen supply (day) | 40.4±2.1 |
Pulmonary hypertension | 12 (3.0) |
Severe neurologic injury (IVH ≥ grade 3 or PVL) | 43 (7.8) |
NEC (≥ stage 2) | 19 (4.7) |
ROP (any stage) | 97 (24.1) |
Type 1 ROP | 46 (11.4) |
Anti-VEGF therapy | 14 (2.7) |
LOS | 88 (21.9) |
Hospital stay (day) | 67.4 ± 35.0 |
Mortality | 16 (3.9) |
Variable | Non-CPI (n = 312) | CPI (n = 90) | p-value |
---|---|---|---|
Gestational age (wk) | 29.1 ± 2.9 | 28.4 ± 3.2 | .007 |
Birth weight (g) | 1,064.7 ± 286.9 | 1,012.5 ± 309.1 | .589 |
Sex | .506 | ||
Male | 154 (49.3) | 48 (53.3) | |
Female | 158 (50.6) | 42 (46.7) | |
Pre-eclampsia | 78 (25.0) | 9 (10.0) | .031 |
Antenatal steroid use | 284 (91.0) | 79 (87.8) | .398 |
IUGR | 107 (34.3) | 26 (28.9) | .338 |
RDS | 177 (56.7) | 61 (67.8) | .068 |
Significant PDA | 127 (40.7) | 40 (44.4) | .531 |
Moderate to severe BPD | 79 (25.3) | 26 (28.9) | .497 |
Postnatal steroid therapy | 72 (23.1) | 24 (26.7) | .496 |
Duration of oxygen supply (day) | 41.4 ± 38.2 | 41.0 ± 38.1 | .163 |
Severe neurologic injury (IVH ≥ grade 3 or PVL) | 34 (10.9) | 9 (10) | .051 |
NEC (≥ stage 2) | 15 (4.8) | 4 (4.4) | .882 |
LOS | 65 (20.8) | 23 (25.6) | .164 |
ROP (any stage) | 71 (22.8) | 26 (28.9) | .021 |
Type 1 ROP | 27 (8.6) | 19 (21.1) | .003 |
Hospital days (day) | 66.5 ± 36.0 | 72.6 ± 36.1 | .154 |
Variable | Any stage ROP |
Type 1 ROP |
||||||
---|---|---|---|---|---|---|---|---|
No ROP (n = 305) | ROP (n = 97) | OR (95% CI) | p-value | No type 1 ROP (n = 356) | Type 1 ROP (n = 46) | OR (95% CI) | p-value | |
Gestational age (wk) | 30.0 ± 2.5 | 25.7 ± 1.7 | 0.872 (0.847–0.897) | < .001 |
30.4 ± 2.8 | 25.1 ± 1.5 | 0.882 (0.853–0.911) | < .001 |
Birth weight (g) | 1,152.5 ± 239.5 | 740.6 ± 212.9 | 0.993 (0.992–0.995) | < .001 |
1100 ± 267.7 | 680.8 ± 198.7 | 0.993 (0.991–0.995) | < .001 |
Male | 157 (51.5) | 49 (50.5) | 1.000 (0.329–1.126) | .339 | 179 (50.3) | 23 (50.0) | 1.000 (0.504–1.305) | .219 |
Pre-eclampsia | 62 (20.3) | 7 (7.2) | 0.919 (0.383–2.205) | .851 | 66 (18.5) | 3 (6.5) | 0.295 (0.089–0.981) | .046 |
Antenatal steroid | 271 (88.9) | 92 (94.8) | 1.547 (0.484–4.942) | .461 | 321 (90.2) | 42 (91.3) | 1.145 (0.388–3.382) | .807 |
IUGR | 114 (37.3) | 19 (19.6) | 0.369 (0.323–1.265) | .199 | 125 (35.1) | 8 (17.4) | 0.389 (0.176–0.860) | .020 |
Moderate to severe BPD | 40 (13.1) | 65 (67.0) | 0.503 (0.361–0.508) | < .001 |
67 (18.8) | 38 (82.6) | 0.467 (0.281–0.410) | < .001 |
Postnatal steroid therapy | 34 (11.1) | 62 (63.9) | 0.512 (0.380–0.531) | < .001 |
60 (16.8) | 36 (78.3) | 0.399 (0.382–0.606) | < .001 |
Duration of oxygen treatment (day) | 27.9 ± 26.1 | 81.2 ± 42.7 | 1.054 (1.042–1.066) | < .001 |
33.5 ± 31.3 | 98.6 ± 38.4 | 1.044 (1.031–1.057) | < .001 |
Placental pathology | ||||||||
CPI | 64 (21.0) | 26 (26.8) | 2.050 (1.170–3.592) | .038 |
71 (19.9) | 19 (46.3) | 2.825 (1.487–5.367) | .002 |
CCA | 33 (10.8) | 10 (10.3) | 0.159 (0.691–3.152) | .159 | 36 (10.1) | 7 (15.2) | 1.590 (0.663–3.816) | .299 |
Chronic deciduitis | 29 (9.5) | 12 (12.4) | 0.244 (0.874–3.872) | .244 | 33 (9.3) | 8 (17.4) | 2.061 (0.887–4.784) | .093 |
VUE | 13 (4.3) | 2 (2.1) | 0.139 (0.042–2.501) | .139 | 15 (4.2) | 0 | 0.237 (0.013–4.413) | .335 |
ACA | 53 (17.4) | 32 (33.0) | 2.079 (1.177–3.671) | .012 |
70 (19.7) | 15 (32.6) | 1.977 (1.012–3.862) | .046 |
MVU | 118 (38.7) | 31 (32.0) | 0.744 (0.452–1.344) | .744 | 134 (37.6) | 15 (32.6) | 0.802 (0.417–1.540) | .507 |
FVTOD | 29 (9.5) | 11 (11.3) | 0.806 (0.325–2.000) | .642 | 36 (10.1) | 4 (8.7) | 0.847 (0.287–2.498) | .763 |
Placental pathology | No ROP |
Any stage ROP |
Type 1 ROP |
|||
---|---|---|---|---|---|---|
Adjusted OR (95% CI) | p-value |
Adjusted OR (95% CI) | p-value |
Adjusted OR (95% CI) | p-value |
|
CPI | 1.008 (0.492–2.068) | .982 | 1.647 (0.702–3.992) | .246 | 2.739 (1.112–6.749) | .029 |
ACA | 0.811 (0.429–1.940) | .811 | 1.267 (0.531–3.023) | .594 | 0.833 (0.319–2.173) | .708 |
MVU | 0.630 (0.315–1.261) | .630 | 2.036 (0.865–4.792) | .103 | 0.570 (0.211–1.539) | .267 |
FVTOD | 0.815 (0.298–2.226) | .690 | 1.080 (0.360–3.240) | .126 | 0.424 (0.141–1.272) | .126 |
Values are presented as mean ± SD, number (%), or mean (IQR). IUGR, intrauterine growth retardation; RDS, respiratory distress syndrome; PDA, patent ductus arteriosus; BPD, bronchopulmonary dysplasia; IVH, intraventricular hemorrhage; PVL, periventricular leukomalacia; NEC, necrotizing enterocolitis; ROP, retinopathy of prematurity; VEGF, vascular endothelial growth factor; LOS, late-onset sepsis; SD, standard deviation; IQR, interquartile range.
Values are presented as mean ± SD or number (%). CPI, chronic placental inflammation; IUGR, intrauterine growth retardation; RDS, respiratory distress syndrome; PDA, patent ductus arteriosus; BPD, bronchopulmonary dysplasia; IVH, intraventricular hemorrhage; PVL, periventricular leukomalacia; NEC, necrotizing enterocolitis; LOS, late-onset sepsis; ROP, retinopathy of prematurity; SD, standard deviation. p < .05.
Values are presented as mean ± SD or number (%). ROP, retinopathy of prematurity; OR, odds ratio; CI, confidence interval; IUGR, intrauterine growth retardation; BPD, bronchopulmonary dysplasia; CPI, chronic placental inflammation; CCA, chronic chorioamnionitis; VUE, villitis of unknown etiology; ACA, amniotic fluid infection/inflammation; MVU, maternal vascular underperfusion; FVTOD, fetal vascular thrombo-occlusive disease; SD, standard deviation. p < .05.
Chronic placental inflammation was statistically associated with type 1 ROP by multiple logistic regression analysis. ROP, retinopathy of prematurity; OR, odds ratio; CI, confidence interval; CPI, chronic placental inflammation; ACA, amniotic fluid infection/inflammation; MVU, maternal vascular underperfusion; FVTOD, fetal vascular thrombo-occlusive disease. p < .05. Adjusted for gestational age, birth weight, sex, duration of oxygen treatment, pre-eclampsia, IUGE and the overlapping placental pathology.